cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study Emerging pharmacotherapies for obesity: A

The pharmacological properties of the novel peptide BPC 157 (PL-10)

Let us clear that up permanently

The regulatory distinction you made is so crucial: the July FDA advisory committee meeting on BPC-157, TB-500, KPV, and others is about compounding access through the 503A pathway, not approval, and not evidence of efficacy

Every treatment is customized to each patient's goals

Your point is a crucial one, and it highlights the deeply felt frustration and perceived inequity experienced by patients with Pernicious Anemia

Where you'll see it in research: Handling notes: The fatty-acid tag gives it longer in vitro stability via albumin binding